{"database": "lobbying", "table": "lobbying_activities", "rows": [[1991496, "9c863313-bc09-450c-a38a-e682718e5be4", "Q2", "CAPITOL HILL STRATEGIES,  LLC", 91774, "BIOGEN INC", 2017, "second_quarter", "MED", "Issues dealing with newborn screening.\nH.R. 2430, the FDA Reauthorization Act (FDARA) of 2017, legislation to reauthorize the Prescription Drug User Fee Act (PDUFA), as reauthorized by the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA).\nIssues dealing with Alzheimer's treatments", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2017-07-18T12:47:58.803000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1991496"], "units": {}, "query_ms": 10.190975153818727, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}